Real-world Data Study of the Efficacy and Toxicity of Nivolumab < em > vs < /em > . Cetuximab and Predictors of Response to Nivolumab in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck in a European Population
CONCLUSION: Effectiveness of nivolumab in terms of OS remains superior to cetuximab. OS, PFS and severe or any grade AEs were superior in both arms of our study compared to those in clinical trials. The AEs profile of nivolumab differed in our study from that in the clinical trials' observations. We have identified four statistically significant prognostic variables on the response to nivolumab in R/M HNSCC.PMID:36974777 | DOI:10.21873/anticanres.16320
Source: Cell Research - Category: Cytology Authors: Lola Macia-Rivas Clara Luz Fernandez-Laguna Cristina Alvarez-Asteinza Ivan Maray Monica Carbajales-Alvarez Ana Lozano-Blazquez Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Clinical Trials | Cytology | Erbitux | Head and Neck Cancer | HNSCC | Skin Cancer | Squamous Cell Carcinoma | Statistics | Study | Toxicology